Skip to content
All posts

Journey Biosciences appoints Greg Dooley & Gordie Nye to its board of directors


Journey Biosciences, Inc., a biotechnology company who recently announced their flagship predictive screening technology—NaviDKD®— is pleased to announce it has appointed two independent non-executive directors with a proven track record of advocacy in the diabetes community to its board of directors, Greg Dooley and Gordie Nye.

“Greg and Gordie both have impressive experiences in consumer products and healthcare organizations,” said Adam Graybill, President and CEO of Journey Biosciences.  “They bring a deep, meaningful connection to the diabetes community from current and past experiences that will be extremely valuable as we launch NaviDKD in the U.S.” 

Additional information about the new directors can be found below:


greg-dooleyGreg Dooley

Greg Dooley brings a wealth of experience to Journey Biosciences as a seasoned finance executive with over two decades of expertise in the field. He currently serves as Vice President Finance, Latin America for The Goodyear Tire & Rubber Company in Akron, Ohio. Greg has significant international experience having spent five years living and working in Brazil, Argentina, and Mexico. His daughter, Isabella, was diagnosed with Type 1 diabetes in 2012 at the age of two while the Dooley Family was living in Mexico City. Greg serves on the Board of Directors for Beyond Type 1, a nonprofit organization changing what it means to live with diabetes. Greg and his wife, Kristina, reside in Hudson, Ohio with their triplets, Mia, Isabella, and Max.


gordie-nyeGordie Nye

Gordie Nye has an impressive track record, having led as CEO in eight different companies across a wide range of industries including diabetes, medical devices, and consumer products. Gordie was an early investor and past board member at Insulet (NASDAQ:PODD) and Atritech (now part of NYSE:BSX) and previously served as board chairman for Atlantic Therapeutics.


About Journey Biosciences

Journey Biosciences is shifting the future of care through predictive innovations. Our flagship solution blends the precision of NaviDKD®, a clinically-validated predictive screening, with the AI-driven insights of Compass, offering up to 12 years of advanced diabetes-related kidney disease (DKD) detection and tailored intervention strategies. This groundbreaking approach improves patient outcomes, optimizes resource allocation, and reduces costs. Discover more about our transformative approach at

For media inquiries: